{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:34Z","timestamp":1791478114160,"version":"4.3.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>As a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment option for melanoma. However, only about half of treated patients could benefit from it in Caucasians, and only about 15% in Chinese melanoma patients. Robust predictive biomarkers are needed. HHLA2, a new-found member of B7 family, is generally expressed in kinds of tumors, such as melanoma. This study focuses on illustrating the prognostic value of HHLA2 in melanoma immunotherapy and its association with tumor-infiltrating lymphocytes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>HHLA2 expression in pan-cancer and the association with prognosis and immune microenvironment were identified by analyzing gene expression profiles from TCGA database with selected bioinformatics tools and methods. Tumor tissues from 81 cases with advanced and unresectable melanoma were collected for detecting HHLA2 and CD8 levels by immunohistochemistry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HHLA2 was found to be ubiquitously expressed in pan-cancer with high level and correlate with the prognosis of patients. Further comprehensive analysis from TCGA database demonstrated that the highly expressed HHLA2 was remarkably correlated with better prognosis, high infiltration status of various immune-active cells and immune activated pathways in skin cutaneous melanoma (SKCM). Moreover, immunohistochemistry (IHC) analyses of FFPE tissue from melanoma patients revealed that HHLA2 high expression was strongly related to improved response to ICB and indicated a longer progression-free survival (PFS) and overall survival (OS). Besides, HHLA2 expression was found to have a positive association with the density of CD8<jats:sup>+<\/jats:sup> TILs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings revealed that high expression of HHLA2 has important values in predicting the response to ICB and indicating improved PFS and OS in patients with advanced and unresectable melanoma, suggesting that HHLA2 may serve as a costimulatory ligand in melanoma, which renders it as an ideal biomarker for immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.902167","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:55:03Z","timestamp":1659941703000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["HHLA2 predicts improved prognosis of anti-PD-1\/PD-L1 immunotherapy in patients with melanoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Fu-xue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-wan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-qin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-zhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-yue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-shi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.08.063","article-title":"Skin cancer in skin of color","volume":"55","author":"Gloster","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.170","article-title":"A new understanding in the epidemiology of melanoma","volume":"10","author":"Erdei","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.32764","article-title":"Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study","volume":"147","author":"Wu","year":"2020","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918763493","article-title":"PD-L1 expression testing in non-small cell lung cancer","volume":"10","author":"Teixido","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction","volume":"4","author":"Grigg","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303524110","article-title":"HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105454","article-title":"Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target","volume":"56","author":"Chen","year":"2019","journal-title":"J Med Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/srep31154","article-title":"HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival","volume":"6","author":"Koirala","year":"2016","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0755-4","article-title":"HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis","volume":"122","author":"Boor","year":"2020","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.007","article-title":"HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival","volume":"442","author":"Yan","year":"2019","journal-title":"Cancer Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00280","article-title":"Over-expression and prognostic significance of HHLA2, a new immune checkpoint molecule, in human clear cell renal cell carcinoma","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2658","article-title":"A new B7:CD28 family checkpoint target for cancer immunotherapy: HHLA2","volume":"21","author":"Xiao","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0733","article-title":"CD28 homolog is a strong activator of natural killer cells for lysis of B7H7(+) tumor cells","volume":"7","author":"Zhuang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7-H5 costimulates human T cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":":02","DOI":"10.1126\/sciimmunol.abf9792","article-title":"KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":":12","DOI":"10.1136\/jitc-2019-000157","article-title":"HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2924","article-title":"Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1-Negative human lung cancers","volume":"24","author":"Cheng","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S325019","article-title":"HHLA2 expression is associated with poor survival in patients with hepatocellular carcinoma","volume":"15","author":"Xu","year":"2021","journal-title":"Biologics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.902167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T06:55:05Z","timestamp":1659941705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.902167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2022.902167"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.902167","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"902167"}}